ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

KALYDECO
Inborn errors of metabolism
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

KALYDECO Rx

Generic Name and Formulations:
Ivacaftor 150mg; tabs.

Company:
Vertex Pharmaceuticals

Therapeutic Use:

Indications for KALYDECO:

Treatment of cystic fibrosis (CF) in patients ≥2yrs who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.

Adults and Children:

<2yrs: not recommended. Oral granules should be mixed with 1 tsp (5mL) of soft-food or liquid (eg, yogurt, applesauce, milk, or juice) and completely consumed. Take with fat-containing food (eg, eggs, butter, peanut butter, cheese pizza, dairy products). 2–<6yrs: (<14kg): 50mg packet every 12 hours; (≥14kg): 75mg packet every 12 hours. ≥6yrs: 150mg tab every 12 hours. Concomitant strong CYP3A inhibitors: 150mg tab or 50mg packet (<14kg) or 75mg packet (≥14kg) twice weekly. Concomitant moderate CYP3A inhibitors: 150mg tab or 50mg packet (<14kg) or 75mg packet (≥14kg) once daily. Moderate hepatic impairment: 150mg tab or 50mg packet (<14kg) or 75mg packet (≥14kg) once daily. Severe hepatic impairment: 150mg tab or 1 packet once daily or less frequently.

Warnings/Precautions:

If genotype is unknown, use an FDA-cleared CF mutation test to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions. Assess ALT/AST levels prior to initiating therapy, every 3 months during the first year of treatment, and annually thereafter. History of ALT/AST elevations: monitor LFTs more frequently. If increased ALT/AST levels develop, monitor closely until abnormalities resolved. Interrupt dosing if ALT/AST is >5xULN; after resolution, consider restarting. Perform baseline and follow-up eye exams. Hepatic impairment. Severe renal impairment or ESRD. Pregnancy. Nursing mothers.

Interactions:

Concomitant strong CYP3A inducers (eg, rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, St. John’s Wort): not recommended. Potentiated by strong CYP3A inhibitors (eg, ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin) and moderate CYP3A inhibitors (eg, fluconazole, erythromycin). May be potentiated by grapefruit and Seville oranges; avoid. Potentiates CYP3A and/or P-gp substrates (eg, digoxin, cyclosporine, tacrolimus).

See Also:

KALYDECO ORAL GRANULES

Pharmacological Class:

Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator.

Adverse Reactions:

Headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, dizziness.

Generic Availability:

NO

How Supplied:

Tabs—56, 60; Oral granules—56

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs